Impact of extended dual antiplatelet therapy on long‐term prognosis in patients with acute coronary syndrome complicated with anemia: A sub‐analysis of the real‐world OPT‐CAD study
Objectives To evaluate the impact of extended dual antiplatelet therapy (DAPT) beyond 12 months on long‐term prognosis in acute coronary syndrome (ACS) patients complicated with anemia undergoing percutaneous coronary intervention (PCI). Background Anemia is frequent among ACS patients and is associ...
Saved in:
Published in | Catheterization and cardiovascular interventions Vol. 98; no. 2; pp. E235 - E242 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken, USA
John Wiley & Sons, Inc
01.08.2021
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Objectives
To evaluate the impact of extended dual antiplatelet therapy (DAPT) beyond 12 months on long‐term prognosis in acute coronary syndrome (ACS) patients complicated with anemia undergoing percutaneous coronary intervention (PCI).
Background
Anemia is frequent among ACS patients and is associated with increased risk of adverse clinical outcomes.
Methods
A total of 6,953 patients were enrolled from the Optimal anti Platelet Therapy for Chinese patients with Coronary Artery Disease (OPT‐CAD) study. A landmark analysis comparing extended DAPT versus single antiplatelet therapy (SAPT) at 12–24 months were performed in anemia patients without premature discontinuation of DAPT before 9 months and major clinical adverse events within 12 months. The primary outcome was major adverse cardiovascular and cerebrovascular events (MACCE), defined as a composite of all‐cause death, myocardial infarction, and stroke.
Results
Patients with anemia (n = 1,728) had higher rates of MACCE, all‐cause mortality, and BARC type 2, 3, 5 bleeding (p < .05) compared to those without anemia (n = 5,225). Anemia patients received extended DAPT (n = 1,010) were associated with a lower risk of stroke (0.3% vs. 1.8%; HR, 0.14; 95% CI, 0.03–0.71; p = .018) compared to those received SAPT (n = 342). The rates of MACCE and all revascularization were lower in patients with extended DAPT, but the differences were not statistically significant. Risk of all‐cause mortality and bleeding were comparable between the two groups.
Conclusions
Extended DAPT beyond 12 months may reduce the incidence of stroke without increasing the risk of bleeding in anemic ACS patients who tolerate 12‐month DAPT. |
---|---|
AbstractList | OBJECTIVESTo evaluate the impact of extended dual antiplatelet therapy (DAPT) beyond 12 months on long-term prognosis in acute coronary syndrome (ACS) patients complicated with anemia undergoing percutaneous coronary intervention (PCI). BACKGROUNDAnemia is frequent among ACS patients and is associated with increased risk of adverse clinical outcomes. METHODSA total of 6,953 patients were enrolled from the Optimal anti Platelet Therapy for Chinese patients with Coronary Artery Disease (OPT-CAD) study. A landmark analysis comparing extended DAPT versus single antiplatelet therapy (SAPT) at 12-24 months were performed in anemia patients without premature discontinuation of DAPT before 9 months and major clinical adverse events within 12 months. The primary outcome was major adverse cardiovascular and cerebrovascular events (MACCE), defined as a composite of all-cause death, myocardial infarction, and stroke. RESULTSPatients with anemia (n = 1,728) had higher rates of MACCE, all-cause mortality, and BARC type 2, 3, 5 bleeding (p < .05) compared to those without anemia (n = 5,225). Anemia patients received extended DAPT (n = 1,010) were associated with a lower risk of stroke (0.3% vs. 1.8%; HR, 0.14; 95% CI, 0.03-0.71; p = .018) compared to those received SAPT (n = 342). The rates of MACCE and all revascularization were lower in patients with extended DAPT, but the differences were not statistically significant. Risk of all-cause mortality and bleeding were comparable between the two groups. CONCLUSIONSExtended DAPT beyond 12 months may reduce the incidence of stroke without increasing the risk of bleeding in anemic ACS patients who tolerate 12-month DAPT. To evaluate the impact of extended dual antiplatelet therapy (DAPT) beyond 12 months on long-term prognosis in acute coronary syndrome (ACS) patients complicated with anemia undergoing percutaneous coronary intervention (PCI). Anemia is frequent among ACS patients and is associated with increased risk of adverse clinical outcomes. A total of 6,953 patients were enrolled from the Optimal anti Platelet Therapy for Chinese patients with Coronary Artery Disease (OPT-CAD) study. A landmark analysis comparing extended DAPT versus single antiplatelet therapy (SAPT) at 12-24 months were performed in anemia patients without premature discontinuation of DAPT before 9 months and major clinical adverse events within 12 months. The primary outcome was major adverse cardiovascular and cerebrovascular events (MACCE), defined as a composite of all-cause death, myocardial infarction, and stroke. Patients with anemia (n = 1,728) had higher rates of MACCE, all-cause mortality, and BARC type 2, 3, 5 bleeding (p < .05) compared to those without anemia (n = 5,225). Anemia patients received extended DAPT (n = 1,010) were associated with a lower risk of stroke (0.3% vs. 1.8%; HR, 0.14; 95% CI, 0.03-0.71; p = .018) compared to those received SAPT (n = 342). The rates of MACCE and all revascularization were lower in patients with extended DAPT, but the differences were not statistically significant. Risk of all-cause mortality and bleeding were comparable between the two groups. Extended DAPT beyond 12 months may reduce the incidence of stroke without increasing the risk of bleeding in anemic ACS patients who tolerate 12-month DAPT. Objectives To evaluate the impact of extended dual antiplatelet therapy (DAPT) beyond 12 months on long‐term prognosis in acute coronary syndrome (ACS) patients complicated with anemia undergoing percutaneous coronary intervention (PCI). Background Anemia is frequent among ACS patients and is associated with increased risk of adverse clinical outcomes. Methods A total of 6,953 patients were enrolled from the Optimal anti Platelet Therapy for Chinese patients with Coronary Artery Disease (OPT‐CAD) study. A landmark analysis comparing extended DAPT versus single antiplatelet therapy (SAPT) at 12–24 months were performed in anemia patients without premature discontinuation of DAPT before 9 months and major clinical adverse events within 12 months. The primary outcome was major adverse cardiovascular and cerebrovascular events (MACCE), defined as a composite of all‐cause death, myocardial infarction, and stroke. Results Patients with anemia (n = 1,728) had higher rates of MACCE, all‐cause mortality, and BARC type 2, 3, 5 bleeding (p < .05) compared to those without anemia (n = 5,225). Anemia patients received extended DAPT (n = 1,010) were associated with a lower risk of stroke (0.3% vs. 1.8%; HR, 0.14; 95% CI, 0.03–0.71; p = .018) compared to those received SAPT (n = 342). The rates of MACCE and all revascularization were lower in patients with extended DAPT, but the differences were not statistically significant. Risk of all‐cause mortality and bleeding were comparable between the two groups. Conclusions Extended DAPT beyond 12 months may reduce the incidence of stroke without increasing the risk of bleeding in anemic ACS patients who tolerate 12‐month DAPT. Abstract Objectives To evaluate the impact of extended dual antiplatelet therapy (DAPT) beyond 12 months on long‐term prognosis in acute coronary syndrome (ACS) patients complicated with anemia undergoing percutaneous coronary intervention (PCI). Background Anemia is frequent among ACS patients and is associated with increased risk of adverse clinical outcomes. Methods A total of 6,953 patients were enrolled from the Optimal anti Platelet Therapy for Chinese patients with Coronary Artery Disease (OPT‐CAD) study. A landmark analysis comparing extended DAPT versus single antiplatelet therapy (SAPT) at 12–24 months were performed in anemia patients without premature discontinuation of DAPT before 9 months and major clinical adverse events within 12 months. The primary outcome was major adverse cardiovascular and cerebrovascular events (MACCE), defined as a composite of all‐cause death, myocardial infarction, and stroke. Results Patients with anemia ( n = 1,728) had higher rates of MACCE, all‐cause mortality, and BARC type 2, 3, 5 bleeding ( p < .05) compared to those without anemia ( n = 5,225). Anemia patients received extended DAPT ( n = 1,010) were associated with a lower risk of stroke (0.3% vs. 1.8%; HR, 0.14; 95% CI, 0.03–0.71; p = .018) compared to those received SAPT ( n = 342). The rates of MACCE and all revascularization were lower in patients with extended DAPT, but the differences were not statistically significant. Risk of all‐cause mortality and bleeding were comparable between the two groups. Conclusions Extended DAPT beyond 12 months may reduce the incidence of stroke without increasing the risk of bleeding in anemic ACS patients who tolerate 12‐month DAPT. |
Author | Zhao, Yu Wang, Xiaozeng Han, Yaling Jiang, Zaixin Li, Jing Ma, Sicong Li, Yi Li, Zhiguo |
Author_xml | – sequence: 1 givenname: Yu orcidid: 0000-0001-7984-4529 surname: Zhao fullname: Zhao, Yu organization: Dalian Medical University – sequence: 2 givenname: Jing surname: Li fullname: Li, Jing organization: General Hospital of Northern Theater Command – sequence: 3 givenname: Sicong surname: Ma fullname: Ma, Sicong organization: General Hospital of Northern Theater Command – sequence: 4 givenname: Zaixin surname: Jiang fullname: Jiang, Zaixin organization: General Hospital of Northern Theater Command – sequence: 5 givenname: Zhiguo surname: Li fullname: Li, Zhiguo organization: General Hospital of Northern Theater Command – sequence: 6 givenname: Xiaozeng orcidid: 0000-0003-1979-0287 surname: Wang fullname: Wang, Xiaozeng organization: General Hospital of Northern Theater Command – sequence: 7 givenname: Yaling orcidid: 0000-0003-4569-6737 surname: Han fullname: Han, Yaling email: hanyaling@163.net organization: General Hospital of Northern Theater Command – sequence: 8 givenname: Yi surname: Li fullname: Li, Yi email: cardiology@163.com organization: General Hospital of Northern Theater Command |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33817946$$D View this record in MEDLINE/PubMed |
BookMark | eNp1kUtuFDEQhi0URB6w4ALIEhuymMSPbveY3agTIFKksJgFu5bHrk4cue3GdmvSO47AgTgNJ8HDDCyQWLlU-vS5qv5TdOSDB4ReU3JBCWGXWpsLJkUjnqETWjO2aJj4cnSoqazEMTpN6ZEQIgWTL9Ax50valP4J-nEzjEpnHHoMTxm8AYPNpBxWPtvRqQwOMs4PENU44-CxC_7-57fvGeKAxxjufUg2YevxqLIFnxPe2vyAlZ4yYB1i8CrOOM3exDDsOsPorC5ecwA9DFa9xyucpk0RK6_cvFOWicq3OIJypb0N0Rl893ld6nZ1hVOezPwSPe-VS_Dq8J6h9YfrdftpcXv38aZd3S40r7lYmOWmp7VgwJQwVa9qKXnFtOlNrSX0VQWVrIzhFe1r0RgCoEnfNKLhVBrS8DP0bq8t-36dIOVusEmDc2X2MKWO1WS5lIwyUtC3_6CPYYplpR1VS96QJeWFOt9TOoaUIvTdGO1Q7tRR0u0S7Uqi3e9EC_vmYJw2A5i_5J8IC3C5B7bWwfx_U9e2V3vlL_4Ss5E |
CitedBy_id | crossref_primary_10_1016_j_ijcha_2024_101377 |
Cites_doi | 10.1056/NEJMoa010615 10.1016/j.jacc.2018.08.1038 10.1016/j.ejim.2018.12.004 10.1161/JAHA.116.003348 10.1001/jama.2019.8146 10.1161/JAHA.119.012741 10.1161/CIRCULATIONAHA.110.009449 10.1016/j.ahj.2012.10.024 10.1056/NEJMoa1409312 10.1093/eurheartj/ehx419 10.1056/NEJMoa1500857 10.1016/S1474-4422(18)30500-3 10.1111/joic.12406 10.1016/j.amjcard.2010.01.001 10.1001/jama.2019.8145 10.1161/CIRCINTERVENTIONS.118.007133 10.1016/j.mayocp.2018.03.030 10.1161/CIR.0000000000000404 10.1038/srep17213 10.1111/1755-5922.12441 |
ContentType | Journal Article |
Copyright | 2021 Wiley Periodicals LLC. |
Copyright_xml | – notice: 2021 Wiley Periodicals LLC. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7T5 7U9 H94 K9. 7X8 |
DOI | 10.1002/ccd.29676 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Immunology Abstracts Virology and AIDS Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Virology and AIDS Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic AIDS and Cancer Research Abstracts MEDLINE CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1522-726X |
EndPage | E242 |
ExternalDocumentID | 10_1002_ccd_29676 33817946 CCD29676 |
Genre | article Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: AstraZeneca Co. Ltd; Sanofi‐Aventis Co. Ltd – fundername: National Key R&D Program of China funderid: 2016YFC1301303; 2016YFC1301300 – fundername: AstraZeneca Co. Ltd; Sanofi-Aventis Co. Ltd – fundername: National Key R&D Program of China grantid: 2016YFC1301303 – fundername: National Key R&D Program of China grantid: 2016YFC1301300 |
GroupedDBID | --- .3N .GA 05W 0R~ 10A 1L6 1OC 29B 33P 3SF 3WU 4.4 4ZD 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 5GY 5RE 5VS 66C 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AAXRX AAZKR ABCQN ABCUV ABEML ABIJN ABJNI ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHMBA AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBD EBS EMOBN F00 F01 F04 F5P FUBAC G-S G.N GNP GODZA H.X HBH HGLYW HHY HHZ HZ~ IX1 J0M JPC KBYEO KQQ LATKE LAW LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NNB O66 O9- OIG OVD P2P P2W P2X P2Z P4B P4D PQQKQ Q.N Q11 QB0 QRW R.K ROL RWI RX1 SUPJJ SV3 TEORI UB1 V2E W8V W99 WBKPD WHWMO WIH WIJ WIK WJL WOHZO WQJ WRC WVDHM WXI WXSBR XG1 XPP XV2 ~IA ~WT CGR CUY CVF ECM EIF NPM .GJ .Y3 31~ 53G AAQQT AASGY AAYXX ACBWZ AZFZN CITATION EJD FEDTE HF~ HVGLF LW6 ZGI 7T5 7U9 H94 K9. 7X8 |
ID | FETCH-LOGICAL-c3536-d8bf1562e2a6d4fa599342cdfd5c9ef44e494dd341f567d0eec0f7767319d073 |
IEDL.DBID | DR2 |
ISSN | 1522-1946 |
IngestDate | Sat Aug 17 04:00:47 EDT 2024 Fri Sep 13 05:14:22 EDT 2024 Fri Aug 23 00:31:04 EDT 2024 Tue Aug 27 13:49:09 EDT 2024 Sat Aug 24 01:03:04 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | dual antiplatelet therapy anemia acute coronary syndrome |
Language | English |
License | 2021 Wiley Periodicals LLC. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c3536-d8bf1562e2a6d4fa599342cdfd5c9ef44e494dd341f567d0eec0f7767319d073 |
Notes | Funding information AstraZeneca Co. Ltd; Sanofi‐Aventis Co. Ltd; National Key R&D Program of China, Grant/Award Numbers: 2016YFC1301303, 2016YFC1301300 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-4569-6737 0000-0001-7984-4529 0000-0003-1979-0287 |
PMID | 33817946 |
PQID | 2559370813 |
PQPubID | 986345 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_2508892120 proquest_journals_2559370813 crossref_primary_10_1002_ccd_29676 pubmed_primary_33817946 wiley_primary_10_1002_ccd_29676_CCD29676 |
PublicationCentury | 2000 |
PublicationDate | August 1, 2021 2021-08-01 2021-08-00 20210801 |
PublicationDateYYYYMMDD | 2021-08-01 |
PublicationDate_xml | – month: 08 year: 2021 text: August 1, 2021 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Hoboken, USA |
PublicationPlace_xml | – name: Hoboken, USA – name: United States – name: Washington |
PublicationTitle | Catheterization and cardiovascular interventions |
PublicationTitleAlternate | Catheter Cardiovasc Interv |
PublicationYear | 2021 |
Publisher | John Wiley & Sons, Inc Wiley Subscription Services, Inc |
Publisher_xml | – name: John Wiley & Sons, Inc – name: Wiley Subscription Services, Inc |
References | 2019; 8 1968; 405 2015; 372 2016; 5 2018; 39 2017; 30 2015; 5 2019; 61 2010; 105 2019; 12 2016; 134 2019; 18 2014; 371 2018; 72 2013; 165 2018; 93 2011; 123 2001; 345 2019; 321 2018; 36 e_1_2_9_20_1 e_1_2_9_11_1 e_1_2_9_22_1 e_1_2_9_10_1 e_1_2_9_21_1 e_1_2_9_12_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 Nutritional anaemias (e_1_2_9_13_1) 1968; 405 e_1_2_9_9_1 e_1_2_9_15_1 e_1_2_9_14_1 e_1_2_9_17_1 e_1_2_9_16_1 e_1_2_9_19_1 e_1_2_9_18_1 |
References_xml | – volume: 123 start-page: 2736 issue: 23 year: 2011 end-page: 2747 article-title: Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium publication-title: Circulation – volume: 372 start-page: 1791 issue: 19 year: 2015 end-page: 1800 article-title: Long‐term use of ticagrelor in patients with prior myocardial infarction publication-title: N Engl J Med – volume: 61 start-page: 48 year: 2019 end-page: 53 article-title: Impact of anemia as risk factor for major bleeding and mortality in patients with acute coronary syndrome publication-title: Eur J Intern Med – volume: 321 start-page: 2428 issue: 24 year: 2019 end-page: 2437 article-title: Effect of P2Y12 inhibitor Monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART‐CHOICE randomized clinical trial publication-title: JAMA – volume: 321 start-page: 2414 issue: 24 year: 2019 end-page: 2427 article-title: Effect of 1‐month dual antiplatelet therapy followed by Clopidogrel vs 12‐month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT‐2 randomized clinical trial publication-title: JAMA – volume: 12 issue: 4 year: 2019 article-title: Influence of baseline Anemia on dual antiplatelet therapy cessation and risk of adverse events after percutaneous coronary intervention publication-title: Circ Cardiovasc Interv – volume: 5 start-page: 17213 issue: 1 year: 2015 article-title: Impact of Anemia and dual antiplatelet therapy on mortality in patients undergoing percutaneous coronary intervention with drug‐eluting stents publication-title: Sci Rep – volume: 18 start-page: 394 issue: 4 year: 2019 end-page: 405 article-title: Stroke in China: advances and challenges in epidemiology, prevention, and management publication-title: Lancet Neurol – volume: 39 start-page: 213 issue: 3 year: 2018 end-page: 260 article-title: 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio‐Thoracic Surgery (EACTS) publication-title: Eur Heart J – volume: 93 start-page: 1448 issue: 10 year: 2018 end-page: 1461 article-title: Outcomes of percutaneous coronary interventions in patients with Anemia presenting with acute coronary syndrome publication-title: Mayo Clin Proc – volume: 72 start-page: 2231 issue: 18 year: 2018 end-page: 2264 article-title: Fourth universal definition of myocardial infarction (2018) publication-title: J Am Coll Cardiol – volume: 30 start-page: 491 issue: 5 year: 2017 end-page: 499 article-title: Baseline anemia in patients undergoing percutaneous coronary intervention after an acute coronary syndrome‐A paradox of high bleeding risk, high ischemic risk, and complex coronary disease publication-title: J Interv Cardiol – volume: 345 start-page: 1230 issue: 345 year: 2001 end-page: 1236 article-title: Blood transfusion in elderly patients with acute myocardial infarction publication-title: N Engl J Med – volume: 8 issue: 16 year: 2019 article-title: Impact of baseline Anemia in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a Prespecified analysis from the VALIDATE‐SWEDEHEART trial publication-title: J Am Heart Assoc – volume: 36 issue: 5 year: 2018 article-title: Predicting long‐term ischemic events using routine clinical parameters in patients with coronary artery disease: the OPT‐CAD risk score publication-title: Cardiovasc Ther – volume: 165 start-page: 143 issue: 2 year: 2013 end-page: 53.e5 article-title: Anemia and mortality in acute coronary syndromes: a systematic review and meta‐analysis publication-title: Am Heart J – volume: 5 issue: 11 year: 2016 article-title: Relationship between Anemia and mortality outcomes in a National Acute Coronary Syndrome Cohort: insights from the UKmyocardial ischemia National Audit Project Registry publication-title: J Am Heart Assoc – volume: 105 start-page: 1385 issue: 10 year: 2010 end-page: 1394 article-title: Impact of Anemia on clinical outcomes of patients with ST‐segment elevation myocardial infarction in relation to gender and adjunctive antithrombotic therapy (from the HORIZONS‐AMI trial) publication-title: Am J Cardiol – volume: 134 start-page: e123 issue: 10 year: 2016 end-page: e155 article-title: 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011 ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and Management of Patients with Stable Ischemic Heart Disease, 2013 ACCF/AHA guideline for the management of ST‐elevation myocardial infarction, 2014 AHA/ACC guideline for the Management of Patients with non–ST‐elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery publication-title: Circulation – volume: 405 start-page: 5 year: 1968 end-page: 37 article-title: Report of a WHO scientific group publication-title: World Health Organ Tech Rep Ser – volume: 371 start-page: 2155 issue: 23 year: 2014 end-page: 2166 article-title: Twelve or 30 months of dual antiplatelet therapy after drug‐eluting stents publication-title: N Engl J Med – ident: e_1_2_9_6_1 doi: 10.1056/NEJMoa010615 – ident: e_1_2_9_11_1 doi: 10.1016/j.jacc.2018.08.1038 – ident: e_1_2_9_15_1 doi: 10.1016/j.ejim.2018.12.004 – ident: e_1_2_9_9_1 doi: 10.1161/JAHA.116.003348 – ident: e_1_2_9_21_1 doi: 10.1001/jama.2019.8146 – ident: e_1_2_9_7_1 doi: 10.1161/JAHA.119.012741 – ident: e_1_2_9_12_1 doi: 10.1161/CIRCULATIONAHA.110.009449 – ident: e_1_2_9_14_1 doi: 10.1016/j.ahj.2012.10.024 – ident: e_1_2_9_19_1 doi: 10.1056/NEJMoa1409312 – ident: e_1_2_9_3_1 doi: 10.1093/eurheartj/ehx419 – ident: e_1_2_9_18_1 doi: 10.1056/NEJMoa1500857 – ident: e_1_2_9_20_1 doi: 10.1016/S1474-4422(18)30500-3 – ident: e_1_2_9_5_1 doi: 10.1111/joic.12406 – ident: e_1_2_9_4_1 doi: 10.1016/j.amjcard.2010.01.001 – ident: e_1_2_9_22_1 doi: 10.1001/jama.2019.8145 – ident: e_1_2_9_16_1 doi: 10.1161/CIRCINTERVENTIONS.118.007133 – volume: 405 start-page: 5 year: 1968 ident: e_1_2_9_13_1 article-title: Report of a WHO scientific group publication-title: World Health Organ Tech Rep Ser contributor: fullname: Nutritional anaemias – ident: e_1_2_9_8_1 doi: 10.1016/j.mayocp.2018.03.030 – ident: e_1_2_9_2_1 doi: 10.1161/CIR.0000000000000404 – ident: e_1_2_9_17_1 doi: 10.1038/srep17213 – ident: e_1_2_9_10_1 doi: 10.1111/1755-5922.12441 |
SSID | ssj0009629 |
Score | 2.3768182 |
Snippet | Objectives
To evaluate the impact of extended dual antiplatelet therapy (DAPT) beyond 12 months on long‐term prognosis in acute coronary syndrome (ACS)... To evaluate the impact of extended dual antiplatelet therapy (DAPT) beyond 12 months on long-term prognosis in acute coronary syndrome (ACS) patients... Abstract Objectives To evaluate the impact of extended dual antiplatelet therapy (DAPT) beyond 12 months on long‐term prognosis in acute coronary syndrome... ObjectivesTo evaluate the impact of extended dual antiplatelet therapy (DAPT) beyond 12 months on long‐term prognosis in acute coronary syndrome (ACS) patients... OBJECTIVESTo evaluate the impact of extended dual antiplatelet therapy (DAPT) beyond 12 months on long-term prognosis in acute coronary syndrome (ACS) patients... |
SourceID | proquest crossref pubmed wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | E235 |
SubjectTerms | acute coronary syndrome Acute Coronary Syndrome - diagnosis Acute Coronary Syndrome - drug therapy Acute coronary syndromes Adverse events Anemia Anemia - diagnosis Antiplatelet therapy Bleeding Cardiovascular disease Cerebral infarction Coronary artery Drug Therapy, Combination dual antiplatelet therapy Heart diseases Humans Mortality Myocardial infarction Patients Percutaneous Coronary Intervention Platelet Aggregation Inhibitors - adverse effects Prognosis Statistical analysis Stroke Treatment Outcome |
Title | Impact of extended dual antiplatelet therapy on long‐term prognosis in patients with acute coronary syndrome complicated with anemia: A sub‐analysis of the real‐world OPT‐CAD study |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fccd.29676 https://www.ncbi.nlm.nih.gov/pubmed/33817946 https://www.proquest.com/docview/2559370813/abstract/ https://search.proquest.com/docview/2508892120 |
Volume | 98 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ1Lj9MwEMdHqz0gLrwfgQUNiAOXdFPHcRo4rQqrBWkBoSLtASly_EAVJVmR5gAnPgIfiE_DJ2HGeawWhIS4Ra1bu50Z-29n5heAR1VldJGYeaznOZ9W5SIuZLKIlSiSypA-9hkXJx-_Ukfv5MuT7GQHno61MD0fYjpw48gI8zUHuK7a_TNoqDF2JgqVM26bQXosiN6eoaMKFZ5QRsuTiGmjrkaqUCL2p0-eX4v-EJjn9WpYcA4vw_txqH2eycdZt61m5utvFMf__C1X4NIgRPGg95yrsOPqa3DheLjVfh1-vAj1k9h4HA_Kkeu2kEyxPt2QRCWLY1--9QWbGjdN_eHnt-881SNnfdVNu25xXeOAbm2Rz3xRm27r0DA4gcaLIzEBp9x26qdvWLtPa_0ED7DtKvpiPeBTeETULZLa3dDLAfmKr9-s6JrcCgMv9wasDp-vlkfx8KiH2KRZqmK7qDztJIUTWlnpdUaySQpjvc1M4byUThbSWlpyfaZymzhnEs8gIppBLM1SN2G3bmp3G1BYZzKRKy1pp5cmRs-tSH2udWYW1NxF8HC0eXnaAz3KHt0sSjJDGcwQwd7oDeUQ023Jm680JwmVRvBgepuikW-x0H_SdNyG08ZIDiQR3Oq9aOolZRgieWIEj4Mv_L37crl8Fi7u_HvTu3BRcLpNyE3cg93t587dI720re6HwPgFUXsXIw |
link.rule.ids | 315,786,790,1382,27957,27958,46329,46753 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwEB6VIgEX_qGBAgPiwCXbrOM4G8SlWqi20C0ILVIvVeT4B626JBXZHODEI_BAPA1Pwtj5qQpCQtyixImdzIz9zXjmC8DTolAyi9Q4lOPURatSFmY8moSCZVGhCB_bxBUnzw_F7AN_fZQcbcCLvham5YcYAm7OMvx87QzcBaR3zlhDldIjlolUXICLZO6Jd6jen5FHZcL_o4wWKBaSqy56XqGI7Qy3nl-N_oCY5xGrX3L2rsFxP9g20-Rk1KyLkfr6G4_j_77NdbjaYVHcbZXnBmyY8iZcmne77bfgx74vocTKYh8rR1e6hSSN5emKUCoJHdsKri9Ylbiqyo8_v313sz26xK-yqpc1Lkvs2FtrdGFflKpZG1SOO4EGjD1pAg7p7dRP27A0n5byOe5i3RT0YNkxqLgRUbdIgHdFpz3rK759t6Bj0iz0lLm3YbH3ajGdhd3fHkIVJ7EI9aSw5Ewyw6TQ3MqEkBNnSludqMxYzg3PuNa06tpEpDoyRkXWcRHRJKJporoDm2VVmi1Apo1KWCokJ2cvjpQcaxbbVMpETai5CeBJL_T8tOX0yFv2ZpaTGHIvhgC2e3XIO7Ouc-d_xSmhqDiAx8NlMki3y0LfpGpcG5c5RoggCuBuq0ZDL7HjQyRVDOCZV4a_d59Ppy_9wb1_b_oILs8W84P8YP_wzX24wlz2jU9V3IbN9efGPCD4tC4eeiv5Ba0TG0U |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VIlVceD8CBQbEgUu2WcdxNnCqdlm1QEuFFqkHpMjxA61YkhXZHODET-AH8Wv4JYydR1UQEuJmJU7sZGbsb-yZzwBPikLJLFLjUI5Tt1qVsjDj0SQULIsKRfjYJi45-ehYHLzjL0-T0y143ufCtPwQw4Kbsww_XjsDX2u7d0YaqpQesUyk4gJc5CJmTqVnb8-4ozLhjyij-YmF5KmLnlYoYnvDo-cnoz8Q5nnA6mec-RV43_e1DTT5OGo2xUh9_Y3G8T8_5ipc7pAo7reqcw22THkddo66vfYb8OPQJ1BiZbFfKUeXuIUki-V6RRiVRI5t_tYXrEpcVeWHn9--u7EeXdhXWdXLGpcldtytNbpFX5Sq2RhUjjmB-os9ZQIOwe3UTluxNJ-W8hnuY90U9GLZ8ae4HlGzSHB3RZc95yu-OVlQmfQKPWHuTVjMXyymB2F31kOo4iQWoZ4UllxJZpgUmluZEG7iTGmrE5UZy7nhGdea5lybiFRHxqjIOiYiGkI0DVO3YLusSnMHkGmjEpYKycnViyMlx5rFNpUyUROqbgJ43Ms8X7eMHnnL3cxyEkPuxRDAbq8NeWfUde68rzglDBUH8Gi4Tebo9ljon1SNq-PixggPRAHcbrVoaCV2bIikiQE89brw9-bz6XTmC3f_vepD2DmZzfPXh8ev7sEl5kJvfJziLmxvPjfmPmGnTfHA28gvXD4Z9A |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Impact+of+extended+dual+antiplatelet+therapy+on+long%E2%80%90term+prognosis+in+patients+with+acute+coronary+syndrome+complicated+with+anemia%3A+A+sub%E2%80%90analysis+of+the+real%E2%80%90world+OPT%E2%80%90CAD+study&rft.jtitle=Catheterization+and+cardiovascular+interventions&rft.au=Zhao%2C+Yu&rft.au=Li%2C+Jing&rft.au=Ma%2C+Sicong&rft.au=Jiang%2C+Zaixin&rft.date=2021-08-01&rft.issn=1522-1946&rft.eissn=1522-726X&rft.volume=98&rft.issue=2&rft_id=info:doi/10.1002%2Fccd.29676&rft.externalDBID=n%2Fa&rft.externalDocID=10_1002_ccd_29676 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1522-1946&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1522-1946&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1522-1946&client=summon |